Scholarlink

Background <p>Aluminum hydroxide-adsorbed venom depot products are promoted for conventional build-up protocols and the maintenance phase of honeybee and <i>Vespula</i> venom immunotherapy (VIT) to improve treatment tolerability and support a&#xa0;sustained immune response. Published data regarding their off-label use during inpatient rush build-up of VIT are scarce.</p> Methods <p>During a&#xa0;recent supply shortage, an aluminum hydroxide-adsorbed depot product instead of the corresponding aqueous venom preparation was used for VIT build-up according to a&#xa0;standardized 3‑day rush protocol in 59&#xa0;consecutive patients. Side effects during VIT build-up and subsequent transition to the maintenance phase of treatment were retrospectively evaluated.</p> Results <p>Local tolerability of the depot product was excellent; VIT-induced large local reactions exceeding 10 cm in diameter were documented in only 3&#xa0;patients (5.1%). There was no indication of an increased rate of VIT-induced systemic reactions. One patient developing a&#xa0;moderately severe anaphylactic reaction on day&#xa0;2 of honeybee VIT build-up promptly stabilized upon antiallergic treatment. No objective systemic reactions were observed during transition to outpatient VIT maintenance using the same depot product.</p> Conclusion <p>Due to their excellent local tolerability, depot preparations represent a&#xa0;promising option for VIT rush build-up.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Rush build-up of venom immunotherapy using a depot preparation: learning from times of shortage

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月31日

查看全文
  • Johanna Stoevesandt,
  • Axel Trautmann

摘要

Background

Aluminum hydroxide-adsorbed venom depot products are promoted for conventional build-up protocols and the maintenance phase of honeybee and Vespula venom immunotherapy (VIT) to improve treatment tolerability and support a sustained immune response. Published data regarding their off-label use during inpatient rush build-up of VIT are scarce.

Methods

During a recent supply shortage, an aluminum hydroxide-adsorbed depot product instead of the corresponding aqueous venom preparation was used for VIT build-up according to a standardized 3‑day rush protocol in 59 consecutive patients. Side effects during VIT build-up and subsequent transition to the maintenance phase of treatment were retrospectively evaluated.

Results

Local tolerability of the depot product was excellent; VIT-induced large local reactions exceeding 10 cm in diameter were documented in only 3 patients (5.1%). There was no indication of an increased rate of VIT-induced systemic reactions. One patient developing a moderately severe anaphylactic reaction on day 2 of honeybee VIT build-up promptly stabilized upon antiallergic treatment. No objective systemic reactions were observed during transition to outpatient VIT maintenance using the same depot product.

Conclusion

Due to their excellent local tolerability, depot preparations represent a promising option for VIT rush build-up.